• Something wrong with this record ?

Palonosetron compared with ondansetron in pediatric cancer patients: multicycle analysis of a randomized Phase III study

G. Kovács, A. Wachtel, E. Basharova, T. Spinelli, P. Nicolas, E. Kabickova,

. 2017 ; 13 (19) : 1685-1698. [pub] 20170601

Language English Country England, Great Britain

Document type Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial

Persistent link   https://www.medvik.cz/link/bmc18033881
E-resources Online Full text

NLK PubMed Central from 2015 to 1 year ago
ProQuest Central from 2005-02-01 to 2020-12-31
Health & Medicine (ProQuest) from 2005-02-01 to 2020-12-31

Links

PubMed 28569078
DOI 10.2217/fon-2017-0189
Knihovny.cz E-resources

AIM: To investigate across multiple cycles the efficacy and safety of palonosetron in the prevention of chemotherapy-induced nausea and vomiting in pediatric cancer patients receiving highly or moderately emetogenic chemotherapy (HEC/MEC). PATIENTS & METHODS: Patients were randomly assigned to 10, 20 μg/kg palonosetron or 3 × 150 μg/kg ondansetron for up to four cycles of HEC/MEC. RESULTS: In all on-study chemotherapy cycles, complete response rates were higher in patients in the 20 μg/kg palonosetron group than the ondansetron group. Treatment-emergent adverse events were comparable between the palonosetron 20 μg/kg and ondansetron groups. CONCLUSION: Over four cycles of HEC/MEC, 20 μg/kg palonosetron was an efficacious and safe treatment for the prevention of chemotherapy-induced nausea and vomiting in pediatric cancer patients.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18033881
003      
CZ-PrNML
005      
20181026105446.0
007      
ta
008      
181008s2017 enk f 000 0|eng||
009      
AR
024    7_
$a 10.2217/fon-2017-0189 $2 doi
035    __
$a (PubMed)28569078
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Kovács, Gábor $u Second Department of Pediatrics, Semmelweis University, Budapest, Hungary.
245    10
$a Palonosetron compared with ondansetron in pediatric cancer patients: multicycle analysis of a randomized Phase III study / $c G. Kovács, A. Wachtel, E. Basharova, T. Spinelli, P. Nicolas, E. Kabickova,
520    9_
$a AIM: To investigate across multiple cycles the efficacy and safety of palonosetron in the prevention of chemotherapy-induced nausea and vomiting in pediatric cancer patients receiving highly or moderately emetogenic chemotherapy (HEC/MEC). PATIENTS & METHODS: Patients were randomly assigned to 10, 20 μg/kg palonosetron or 3 × 150 μg/kg ondansetron for up to four cycles of HEC/MEC. RESULTS: In all on-study chemotherapy cycles, complete response rates were higher in patients in the 20 μg/kg palonosetron group than the ondansetron group. Treatment-emergent adverse events were comparable between the palonosetron 20 μg/kg and ondansetron groups. CONCLUSION: Over four cycles of HEC/MEC, 20 μg/kg palonosetron was an efficacious and safe treatment for the prevention of chemotherapy-induced nausea and vomiting in pediatric cancer patients.
650    _2
$a mladiství $7 D000293
650    _2
$a antiemetika $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D000932
650    _2
$a protinádorové látky $x škodlivé účinky $x terapeutické užití $7 D000970
650    _2
$a dítě $7 D002648
650    _2
$a předškolní dítě $7 D002675
650    _2
$a lidé $7 D006801
650    _2
$a kojenec $7 D007223
650    _2
$a novorozenec $7 D007231
650    _2
$a isochinoliny $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D007546
650    _2
$a nauzea $x farmakoterapie $x etiologie $7 D009325
650    _2
$a nádory $x komplikace $x farmakoterapie $7 D009369
650    _2
$a ondansetron $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D017294
650    _2
$a chinuklidiny $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D011812
650    _2
$a výsledek terapie $7 D016896
650    _2
$a zvracení $x farmakoterapie $x etiologie $7 D014839
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Wachtel, Antonio $u Department of Pediatrics, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru.
700    1_
$a Basharova, Elena $u Oncohematology Center, Chelyabinsk Pediatric Regional Clinical Hospital, Chelyabinsk, Russia.
700    1_
$a Spinelli, Tulla $u Helsinn Healthcare SA, Lugano, Switzerland.
700    1_
$a Nicolas, Pierre $u Helsinn Healthcare SA, Lugano, Switzerland.
700    1_
$a Kabickova, Edita $u Department of Pediatric Haematology & Oncology, Charles University & University Hospital Motol, Prague, Czech Republic.
773    0_
$w MED00008687 $t Future oncology (London, England) $x 1744-8301 $g Roč. 13, č. 19 (2017), s. 1685-1698
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28569078 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20181008 $b ABA008
991    __
$a 20181026105957 $b ABA008
999    __
$a ok $b bmc $g 1340335 $s 1030875
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 13 $c 19 $d 1685-1698 $e 20170601 $i 1744-8301 $m Future oncology $n Future Oncol $x MED00008687
LZP    __
$a Pubmed-20181008

Find record

Citation metrics

Archiving options